Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

November 5, 2026

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings

Earnings Call Speaker Segments

Harrison Aaron

executive
#1

Thanks, Stephanie, and thanks to everyone for being with us today as we go through Cronos' Q3 2026 financial and business performance. Joining me on this call are our Chairman, President, and CEO, Mike Gorenstein, along with our CFO, Anna Shlimak. This morning Cronos put out a news release announcing our financial results, and that release is filed on our EDGAR and SEDAR+ profiles. You'll also find this information and the prepared remarks posted on our website under Investor Relations. Before handing the call to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Those forward-looking statements rest on management's current expectations and assumptions, and they're subject to risks and uncertainties that could cause actual results to differ materially from what those forward-looking statements project. The factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and in our SEC filings, which are available on our website, and any forward-looking statements made during this call are qualified in their entirety by those documents. Details on non-GAAP financial measures, including reconciliations to U.S. GAAP, are likewise available in the earnings materials on our website. Finally, throughout this conference call we will be making statements regarding market share information, and unless otherwise stated, all market share data is provided by HiFyre. We'll now make our prepared remarks, and after that we'll move to a question-and-answer session. With that, I'll pass it over to Cronos' Chairman, President, and CEO, Mike Gorenstein.

Michael Gorenstein

executive
#2

Thank you, Harrison. Cronos delivered an exceptional third quarter, setting organic records across net revenue, gross profit, and adjusted EBITDA—results that demonstrate solid execution of our borderless product strategy throughout each market we serve. Starting with Israel, Cronos recorded its 11th consecutive quarter of record net revenue, rising 33% year-over-year, which equals 19% growth on a constant currency basis, and pharmacy data gathered by Cronos shows the PEACE NATURALS brand reinforcing its leading position. Our value brand LIT also added to growth during the quarter. Turning to Canada, we reached record net revenue, and compared with industry-wide sales growth of 1%, our brands generated 41% year-over-year retail sales growth. The Spinach brand had another outstanding quarter, with market-leading share gains that highlight how effective our innovation engine is. In Canada, Spinach kept its #1 spot in vapes for a third quarter in a row, and total vape market share grew to 11.4%. In the vape cartridge subcategory, Spinach held #1 for a fourth consecutive quarter, with share growing to 12.1%. In the all-in-one vape subcategory, Spinach share grew to 10.2% as our PUFFERZ all-in-one innovation keeps building market traction. During the third quarter, we kept using our proven flavor development process, adding two new flavor profiles to the Spinach vape cartridge lineup: the Strawberry Banana 1.2g vape and the Sweet Citrus Punch 1g liquid diamond vape. Then in October, we brought back the seasonal limited edition Sweet Green Apple 1g vape. On the edibles side, SOURZ by Spinach held onto the #1 brand spot in Canada for a ninth quarter in a row, with market share rising to 21.8% and its share of gummies growing to 23.6%; during Q3, four of the top 7 edible SKUs in Canada were SOURZ by Spinach Fully Blasted products, among them the country's #1 edible, the Fully Blasted Blue Raspberry Watermelon 10-pack. And in September, we expanded the SOURZ by Spinach range with the launch of Fully Blasted Blue Raspberry Lemonade gummies, which are the brand's first gummies made with 100% live resin. During October, we introduced Caramel Green Apple into the Fully Blasted SOURZ lineup for the very first time, as a limited edition product offered this autumn. On the flower side, Spinach came in third across Canada, and its share of the market climbed to 6.1%, while two Spinach SKUs landed among the country's seven best-selling flower items. Demand for our products remains robust, which is keeping flower supply constrained, despite the additional capacity delivered by the GrowCo expansion late in 2025. Turning to pre-rolls, Spinach continued climbing the rankings to fifth place in Canada, with share rising to 3.3%. Among infused pre-rolls, Spinach took sixth place as its market share grew to 3.8%. In the traditional pre-roll category, Spinach likewise placed sixth, with share up to 3%. Now, looking at our remaining global markets apart from Israel, we achieved record net revenue there. That figure climbed sevenfold compared with the same period a year earlier — moving from $1.9 million up to $13.2 million — with sustained strong demand in Germany driving the result. Broadening our reach internationally continues to serve as an important engine of growth as we carry out our borderless product strategy. During October, we completed the acquisition of CanAdelaar, which stands as the largest adult-use cannabis operator in Europe, and I feel real excitement about what this means for Cronos. The Netherlands is a market that operates unlike any other, and it stands apart from the adult-use markets legalized throughout North America. A retail cannabis framework has been in place for close to 50 years, under a policy in which coffeeshops were tolerated by the government to sell cannabis in a restricted manner, and from the consumer's point of view it has effectively functioned as a legal market throughout that whole period. No excise tax policy exists that puts the legal market at a disadvantage. The experiment gives retailers more product formats and lets them carry more inventory than those operating in the tolerated market. Wholesale transactions between growers are permitted under the experiment, and solvent-based extraction is not allowed. Retailers in the experiment also compete with stores in the legacy-tolerated market in neighboring municipalities, where fewer product formats are available. That lessens some of the swings we observe in other newly launched adult-use markets. Even so, just like any newly launched adult-use market, we still expect prices to compress, given that suppliers have now had a chance to scale up and satisfy demand. Still, since the base purchase price came in under 3x trailing adjusted EBITDA, we didn't pursue this acquisition anticipating near-term price stability or quick growth. Notwithstanding the 50-year-old coffeeshop network, the market is still fairly immature. Prior to the experiment, the supply side had never been permitted in the way the retail side was, so it has not benefited from years of steady investment in R&D and operational efficiencies. Furthermore, the experiment opens the door to new formats like vapes and gummies. That's where we think we can create value: by applying efficiencies we've learned from producing at Cronos and by spending to launch our borderless products. Over time, we expect those investments to compound, just as they have in the other markets where we operate. We believe the upside gets amplified by the possibility that the experiment in the Netherlands expands. This aligns with our strategy of building a portfolio of borderless products and bringing them into new markets as regulations open up. In closing, we see three ways this acquisition could produce asymmetric value over the long term: 1. Launching our borderless products and boosting operational efficiency. 2. We stand to gain from possibly widening the pilot, which right now reaches under 10% of the population. 3. Using the Netherlands as a base to roll out our branded products throughout Europe — we see great long-term promise there, and we are only at the beginning. I'll now hand things over to Anna, who will take you through the financials for the third quarter.

Anna Shlimak

executive
#3

Thanks, Mike, and good morning, everyone. Cronos recorded consolidated net revenue of $63.5 million for the third quarter of 2026, up 75% compared with the same period a year earlier. The increase in net revenue was driven primarily by greater sales of cannabis flower in Israel, Canada, and other countries — Germany in particular — as well as stronger cannabis extract sales within the Canadian market; we note that, historically, Canadian Provincial Board purchasing can show seasonal softness in Q4 relative to Q3, and that international sales outside Israel may be uneven from one quarter to the next because of the timing of export permits and shipments. Gross profit for the third quarter came to $32.3 million, which represents 76% growth year-over-year from Q3 2025. The main driver of that year-over-year gain was higher average selling prices—mostly from a shift in mix toward Israel and other markets where no excise taxes apply—along with greater sales volumes. Those larger volumes lifted net revenue and also produced efficiencies through better absorption of overhead costs. As we mentioned last quarter, gross margins can fluctuate between quarters because of things such as seasonality, the mix of products and geographies, production levels, and possible price compression. For that reason, we view gross margin results measured across a trailing 12-month window as more informative than looking at any one quarter on its own. Operating expenses for the quarter totaled $23.3 million, up $4.4 million from a year earlier, with the rise coming from higher G&A and sales and marketing costs. Operating expenses rose 23% compared with the prior year, while net revenue grew 75% year-over-year; as a result, total OpEx as a share of net revenue fell from 52% in Q3 2025 to 37% in Q3 2026. Third-quarter Adjusted EBITDA reached a record $17.1 million, up $11.4 million from a year earlier, thanks to greater gross profit that was partly offset by higher operating expenses. Now looking at the balance sheet and cash flow statement: the company closed the quarter with $841 million across cash, cash equivalents, restricted cash, short-term investments, and non-current interest-bearing deposits. That figure is $14 million above Q2 2026, reflecting $34 million of cash flow from operations, which gained from a $12 million working capital inflow. Those items were partly balanced out by $10 million in CapEx, $9 million used for share repurchases, and a $1 million hit from foreign exchange. Beyond that $841 million, we also have $18 million in loans receivable plus $5 million in other investments. To sum up, Q3 brought record results for net revenue, gross profit, and adjusted EBITDA, and we're still seeing robust business momentum thanks to our focused strategy along with the dedication and execution of our team; with that, I'll turn things over to the operator for Q&A.

Kenric Tyghe

analyst
#4

Mike, if you don't mind, regarding how things went in Germany, could you help us square that with what some of your competitors have said lately? What portion of it would you attribute simply to robust demand pull for Cronos' product, and what portion to the uneven timing of export permits that Anna mentioned?

Michael Gorenstein

executive
#5

That's a really good question. There's been considerable talk about price compression. While price compression is indeed real to some degree, we continue to view it as accretive overall to our margins in the business. Generally speaking, we simply haven't had supply available, and as long as this remains an allocation exercise, there's definitely some lumpiness, though much of it comes down to having more supply on hand to ship as we've scaled up. We still expect growth in Germany going forward, but I continue to see us distributing it across a 12-month period.

Kenric Tyghe

analyst
#6

Right, thanks. And building on that, one more question. In your prepared remarks you mentioned supply being tight even with the capacity expansion. Does what you're seeing out there — and the success you're having in markets like Germany — lead you to rethink that next growth phase at GrowCo, or possibly pull it forward? Or will you wait for things to settle before you revisit the timing of any further expansion?

Michael Gorenstein

executive
#7

That's a great question, I think. The key thing for us is simply making sure that, when we consider expansion, we aren't just focused on bringing something online to cover a demand shortfall a few months out; what we're building needs to be durable and efficient for years ahead. So our view is really long-term. We want to make sure every T is crossed and every I is dotted, but we are definitely examining what can help drive growth in the future.

Kenric Tyghe

analyst
#8

Anna, how at ease are you — if you had to sort of frame the margin profile for the quarter, what risks do you see surrounding the current margin profile as you look toward the fourth quarter? I believe you mentioned some of that possible Canadian board-level weakness, but more specifically, when we look ahead to 2027, given how margins have moved through the year, how comfortable are you with where we stand?

Anna Shlimak

executive
#9

Sure. I think that trailing 12-month period gives us kind of the most helpful context for our margin; and you've witnessed that fluctuation across the year; so, I think that's kind of where we're going to stay. I would say going forward, that's kind of where we believe we'll be.

Kenric Tyghe

analyst
#10

All right, that's all from me. Many thanks. I'll rejoin the queue, and congratulations once more.

Ryan Neal

analyst
#11

Ryan here, sitting in for Derek. Clearly, up in Canada, we've witnessed a pattern where derivative segments have captured a sizable portion of flower's share across the years. I'm curious whether you expect a comparable pattern to play out in the Dutch market?

Michael Gorenstein

executive
#12

That seems fair to anticipate, and when regulations allow it, I'd expect that to happen in virtually every market eventually. As I mentioned earlier, the market there has existed for 50 years from a consumer standpoint, yet the experiment is really the first chance for legal sales. You've got vapes and edibles. Pre-rolls have existed. What stands out most in the Netherlands is simply how common hash is. Hash is quite popular there relative to North America; but a major element of our thesis involves bringing those borderless products across, establishing genuine loyalty in certain repeatable, well-defined products, and we believe that trend will align with North America.

Ryan Neal

analyst
#13

Great, and then perhaps just one question about the macro picture — any update on that would be helpful, specifically regarding whether people are trading up to more value-oriented products, etc.

Michael Gorenstein

executive
#14

No, on macro, we have definitely observed — in Germany, I think, is where a lot of attention is concentrated at the moment, but I think that has more to do with the market maturing. In any new market, you can expect price compression to show up, and you can expect that as supply ramps up, you begin to approach equilibrium, but overall we have seen relative stability. I think it is just important that, as long as we are offering a strong value proposition, I think you will still have people who see the value in what is kind of the mainstream category. But outside of differences in product formats or what you would expect typical and seasonal shopping to reflect, we have not really seen any major shifts.

Ryan Neal

analyst
#15

All right, thank you, and congratulations once more.

Pablo Zuanic

analyst
#16

I have two questions about the Netherlands. First, regarding your expectation that the pilot will be expanded — do you mean within the current 4 years, or after the pilot concludes at the end of those 4 years? On the same topic, we've noticed a drop in the count of coffeeshops. I believe we're at 70 or 71 at present. What is causing that, how fast are towns able to grant those licenses to others, and can towns add further coffeeshops past the initial license?

Michael Gorenstein

executive
#17

Thank you; so, yes, my reference was to the close of that period. I believe many other municipalities are quite interested in joining the experiment. There has, I think, been discussion about expanding before that date, but given the legislative process, it seems hard to do. We would of course welcome it, yet it is definitely not something we would count on. As for your second question, on the coffeeshop count: I think that relates more to the regulations and to what is going on with each individual coffeeshop. A few are set to come back online, so I think we still end up net with a few more than where we began, but nothing moves very quickly when it comes to the permitting and going through the various approval processes. That said, it isn't business-related; it is really more about regulation and specific to the coffeeshop. So I think you may see a few more added, and whether more get added is really up to the municipalities. But some of these have had queues of something like 15 years — I think one of the newer ones took that long just to be able to open. Plenty of people are interested in doing it, but generally you're seeing quite a long road for these new stores to open.

Pablo Zuanic

analyst
#18

Right, thanks. Then one more question about the Netherlands. So regarding your capacity as greenhouse — you've got the biggest capacity, and you play more in the — I'm not sure whether you'd call it value or mainstream segment. We're seeing additional capacity coming from other players, but those are more, I suppose, higher-priced products, indoor. Perhaps they don't enjoy the same cost flexibility as you do. So when we discuss price compression, in theory that would work in your favor, since it would squeeze the margins of the others, while you're very well positioned given what you have. But tell me if I'm wrong about that whole description. And the second part of the question: regarding broadening the product portfolio, how fast can you do that? Particularly on the extract side that you mentioned.

Michael Gorenstein

executive
#19

Thank you. I believe that's quite an accurate characterization. Naturally, if we had the choice, we'd be pleased with the current level of pricing, but one reason we favor this asset is that we believe our supply base is differentiated, and I think that matters a great deal. We're nowhere near full utilization, so we can ramp up. And we also expect cost improvements to come from various efficiencies we can implement, particularly in genetics. I think that certainly is something we believe provides us with long-term upside here. And regarding what we can accomplish with derivative products, one interesting aspect of this market is that, since there are no B2B sales among the different companies the way there are in most other markets we examine, I think the efficiency of the grow matters even more, because you're essentially using your own product as inputs. So I think that's something we consider. And it really comes down to how quickly we bring products to market. I think we already have much of the development work completed and the experience in making them; it's simply doing so in a manner where we can check the calendar and ensure we're giving them the proper attention they need at retail to have the right messaging. We don't want to overcrowd or flood, just launching everything at once. So we'll have a fairly steady calendar. I think we can bring products to market relatively quickly. But still, we want to pace it so that we can ensure the sell-in is done properly and ensure the team is manufacturing everything up to our standards; and again, taking a very long-term view on how we get the product out.

Pablo Zuanic

analyst
#20

Thanks. A final question about Germany. I realize we've discussed previously putting money into a downstream route to market there. My understanding is that you mainly depend on local distributors and importers in that country; it's hypothetical, of course, but if the OGI-Aurora transaction closes, then in my view there would be considerable overlap in the European route to market, and perhaps personnel and assets might emerge and become available, which would give you a chance to build your RTM or reinforce it organically in Germany. Is my thinking correct on that, and would that be an opportunity?

Michael Gorenstein

executive
#21

Yes, look, I'd say your thinking is correct. We're opportunistic at all times. What we've been concentrating on for now, I think, is ensuring we can secure the right supply and that we have sufficient supply to satisfy demand. We believe we've gained pretty good traction to date and managed to reach the market, yet I haven't sensed a squeeze or any kind of urgency suggesting we'd lose out on distribution assets without an immediate move; that said, I do think, yes, opportunities to do so will keep increasing. So we remain patient and disciplined. Still, I believe that provided we continue concentrating on having the best supply available, we'll be well positioned for Germany.

Operator

operator
#22

That wraps up the question-and-answer portion. Thanks for joining today's conference. That brings the program to a close. You can disconnect at this point. This live transcript is generated automatically, with no human involvement or review.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.